13F Holdings
中文EN

ZLAB Zai Lab Ltd

Pharmaceutical Preparations · Nasdaq · SEC CIK 1704292 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.0%
TTM net income YoY4.1%
TTM EPS YoY5.3%
Revenue 3-yr CAGR18.8%
Net income 3-yr CAGR—

Margins

Gross margin54.7%
Operating margin-63.0%
Net margin-44.9%
FCF margin-37.0%
EBITDA margin-60.1%

Returns

ROE-30.0%
ROA-18.2%
ROIC (approx.)-779.4%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets45.0%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-45.16x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$460.16M$398.99M$266.72M$215.04M$144.31M
Cost of revenue$190.52M$147.12M$95.82M$74.02M$52.24M
Gross profit$269.64M$251.87M$170.90M$141.02M$92.07M
R&D expense$220.90M$234.50M$265.87M$286.41M$573.31M
SG&A expense$277.61M$298.74M$281.61M$258.97M$218.83M
Operating income-$229.43M-$282.12M-$366.57M-$404.36M-$700.06M
Interest expense$5.21M$2.25M$0$0$0
Pretax income-$178.46M-$257.10M-$334.62M-$443.29M-$704.47M
Income tax-$2.93M$0$0$0$0
Net income-$175.54M-$257.10M-$334.62M-$443.29M-$704.47M
EBITDA-$214.42M-$270.26M-$357.54M-$396.13M-$693.58M
EPS (basic)-0.16-0.26-0.35-0.46-0.76
EPS (diluted)-0.16-0.26-0.35-0.46-0.76
Weighted avg. shares (diluted)1.10B989.48M966.39M958.07M929.92M
Balance sheet
Cash & equivalents$679.57M$449.67M$790.15M$1.01B$964.10M
Short-term investments$10.00M$330.00M$16.30M$0$445.00M
Receivables$106.12M$85.18M$59.20M$39.96M$47.47M
Inventory$74.75M$39.88M$44.83M$31.62M$18.95M
Current assets$1.02B$1.05B$939.61M$1.12B$1.50B
PP&E, net$47.39M$47.96M$53.73M$57.86M$43.10M
Intangibles$76.14M$56.03M$13.39M$1.51M$1.85M
Total assets$1.17B$1.19B$1.04B$1.22B$1.61B
Current liabilities$416.17M$299.38M$203.07M$139.84M$192.90M
Short-term debt$204.53M$131.71M$0——
Total liabilities$456.88M$344.86M$240.18M$174.54M$230.00M
Shareholders' equity$715.50M$840.90M$796.12M$1.05B$1.38B
Shares outstanding1.11B1.08B972.24M960.22M954.98M
Cash flow statement
Operating cash flow-$150.79M-$214.87M-$198.18M-$367.64M-$549.23M
Capital expenditure$8.10M$5.66M$7.21M$24.59M$18.30M
Free cash flow-$158.89M-$220.53M-$205.39M-$392.23M-$567.53M
Investing cash flow$307.87M-$375.19M-$10.78M$420.02M$249.96M
Financing cash flow$72.35M$349.89M-$6.43M-$1.73M$820.20M
Depreciation & amortization$15.01M$11.86M$9.03M$8.23M$6.49M
Stock-based compensation$65.60M$70.65M$79.63M$61.30M$40.71M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.